Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Investigation

Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas

Karin Schumacher, Wolfgang Haensch, Claudia Röefzaad and Peter M. Schlag
Karin Schumacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Haensch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Röefzaad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. Schlag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Presence of CD8+ T cells within esophageal carcinomas is often scattered (A) or CD8+ T lymphocytes are located mainly in the stroma surrounding epithelial complexes (B), whereas infiltration within the epithelial tumor cell nests can be colocalized with proliferation markers (C) and IFN-γ immunoreactivity (D). Immunofluorescence analysis of frozen sections was performed with CD8 (A–D), Mib-1 (C), and IFN-γ (D) as described in “Materials and Methods.” Alexa Fluor 488-conjugated goat antirat IgG (green) was used as a second-step reagent for CD8 cell detection. Alexa Fluor 568-conjugated goat antimouse IgG (red) served for detection of IFN-γ and Mib-1 immunofluorescence, respectively. Nuclear counterstaining was performed with propidium iodide (red, A and B) or DAPI (blue, D) or was not performed (C), and overlays of the stainings are shown. A, SC presence of CD8+ T cells within a UICC stage IV SCC. B, p.t. localization of CD8+ T cells within a UICC stage III SCC. D, colocalization of IFN-γ secretion and CD8 T cell presence in a UICC stage II SCC patient with i.t. CD8+ T cell infiltrations. Results obtained by quantitative mRNA analysis of this patient (P1) are shown in Table 2 <$REFLINK> . Note also the presence of proliferative CD8+ T cells within the tumor (C). Original magnifications: B, ×200; A, C, and D, ×400.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Time-to recurrence (A) and Time-to death (B) rates are improved in patients as amounts of CD8+ T cells within the tumors increase. For details in the determination of CD8+ T cells within the 70 completely resected primary esophageal tumors, see “Materials and Methods.” +, censored cases; IT, i.t.; PT, p.t.; SC/0, scattered or no presence of CD8+ T cells within esophageal carcinomas.

Tables

  • Figures
  • Table 1

    Presence of CD8+ T cells within esophageal tumors decreases with tumor progression

    Levels of CD8+ T cells were estimated in 70 patients after complete resection of primary esophageal carcinomas as described in “Materials and Methods.” Statistic analysis was performed using the χ2 test. Statistical significance was set at P < 0.05. Data in parentheses are percentages.
    CD8+ T cells
    Total primary tumors (70 cases)No. of casesi.t.p.t.SC/nilP
    pT Stagea0.008
     pT1134 (31)7 (54)2 (15)
     pT2237 (30)4 (17)12 (52)
     pT3280 (0)9 (32)19 (68)
     pT450 (0)1 (20)4 (80)
    Lymph node metastasisa0.015
     pN0237 (30)7 (30)9 (40)
     pN+474 (8)15 (32)28 (60)
    Tumor gradinga0.040
     Low63 (50)2 (33)1 (17)
     Moderate273 (11)9 (33)15 (56)
     High375 (13)11 (30)21 (57)
    Histotype0.112
     Adenocarcinoma378 (22)8 (22)21 (56)
     SCC333 (9)14 (43)16 (48)
    • a Classified according to Tumor-Node-Metastasis classification. pT, tumor size; pN, lymph node involvement.

  • Table 2

    Reactivity of CD8+ T cells within and around esophageal tumors

    Representative examples for quantitative PCR on tumor (Tm) and adjacent normal mucosa (Nm) samples from patient P1 with i.t. CD8+ T cell infiltrations and patient P2 with p.t. location of CD8+ T cells. Mean values of triplicate analysis are shown. Comparative immunofluorescence staining for patient P1 is shown in Fig. 1 <$REFLINK> .
    PatientCD8IFN-γβ-actinCD8/β-actinaIFN-γ/CD8b
    CD8+ i.t.P1:Tm30.8534.4020.231.521.12
    P1:Nm29.7232.1121.831.361.08
    CD8+ p.t.P2:Tm33.3535.7227.791.201.07
    P2:Nm33.3735.9221.781.531.08
    PBMCc32.1934.9725.221.281.09
    CD8+ flud24.1827.9920.151.201.16
    • a Values represent copies of CD8 mRNA per copies of β-actin mRNA.

    • b Values represent copies of IFN-γ mRNA per copies of CD8 mRNA.

    • c Controls included unstimulated CD8+ T cells from PBMC.

    • d Controls included influenza-matrix peptide-specific CD8+ T cells 2 h after peptide restimulation (see also Refs. 17 , 18 , and 20 ) that were generated from PBMC as described in “Materials and Methods.”

  • Table 3

    Time-to recurrence and time-to death dates in esophageal cancer patients depend on localization and amount of CD8+ T cells within the tumors

    Presence of i.t., p.t., or SC or no CD8+ T cells in 70 primary carcinomas of the esophagus was compared to clinical follow-up. Median time to recurrence and median time to death dates are listed. Data in parentheses are ranges. As a control follow-up data for nodal negative (pN0) vs nodal positive patients (pN+) are also shown.
    No. of PatientsTime to recurrence (mo)Recurrence (no.)Log rankTime to death (mo)Death (no.)Log rank
    CD8+ i.t.11–0–0
    CD8+ p.t.2220 (7–32)130.000350 (10–89)90.0004
    CD8+ SC/03716 (12–20)2518 (10–25)21
    pN0a2344 (35–55)645 (37–51)5
    pN+4716 (13–18)320.000433 (23–44)250.0029
    • a Classified according to Tumor-Node-Metastasis classification.

  • Table 4

    Univariate and multivariate analyses of prognostic factors for survival

    Univariate analysisMultivariate analysis
    Log rankBreslowRelative risk95% Confidence intervalP
    i.t. CD8+ T cells (present)a0.00040.00450.50.34–0.730.0004
    UICC stage (I–IV)0.00100.00322.31.50–23.530.0001
    Nodal stage (pN+)0.00290.00203.91.47–10.410.0060
    Histotype (adenocarcinoma/SCC)0.77380.73021.10.54–2.290.7768
    • a CD8+ T cell infiltration within the tumor is a factor (variable) related to a favorable survival with the relative risk below 1.0.

PreviousNext
Back to top
Cancer Research: 61 (10)
May 2001
Volume 61, Issue 10
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas
Karin Schumacher, Wolfgang Haensch, Claudia Röefzaad and Peter M. Schlag
Cancer Res May 15 2001 (61) (10) 3932-3936;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic Significance of Activated CD8+ T Cell Infiltrations within Esophageal Carcinomas
Karin Schumacher, Wolfgang Haensch, Claudia Röefzaad and Peter M. Schlag
Cancer Res May 15 2001 (61) (10) 3932-3936;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients
  • Abstract B84: Physiologic pancreatic cancer imaging using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
  • Abstract B83: Targeting TRPV6 oncochannel for the treatment of pancreatic cancer: A Phase I trial experience
Show more Clinical Investigation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement